BioCentury
ARTICLE | Company News

Sept. 17 Company Quick Takes: Priority Review for Merck Ebola vaccine; plus Edgewise’s debut, Adaptive, AskBio and Acceleron

September 17, 2019 11:38 PM UTC

Merck Ebola vaccine granted Priority Review
FDA accepted and granted Priority Review to a BLA from Merck & Co. Inc. (NYSE:MRK) for its Ebola vaccine V920 (rVSV-ZEBOV). The candidate has a PDUFA date of March 14, 2020. HHS’s Biomedical Advanced Research and Development Authority (BARDA) is providing $23 million over the next year to Merck to support the vaccine’s development.

DMD company Edgewise debuts with $50M B round
Edgewise Therapeutics (Boulder, Colo.) emerged from stealth Tuesday with $50 million in series B funding to bring lead candidate EDG-001, a muscle stabilizer for Duchenne and Becker muscular dystrophies, through clinical proof of concept as well as expand its pipeline of musculoskeletal small molecule therapies...